Cardiovascular risk reduction: As of October 2025, the 7 mg and 14 mg doses are FDA-approved to lower the risk of major adverse cardiovascular events such as heart attack or stroke in adults with type 2 diabetes who are at high cardiovascular risk
Discontinuation is rarely required solely for constipation but may be appropriate if symptoms prove refractory to all interventions or if serious complications develop
Download our GLP-1 app to Turn Your Weight Loss Journey into Your Favorite Game Blood tests give periodic snapshots, and tracking day-to-day habits, symptoms, and consistency helps you see patterns labs alone miss
For Wegovy-specific dose tracking, see the Wegovy Tracker and Wegovy Side Effect Tracker App pages
Int J Clin Pharmacol Res 1992;12:299-304
Minor variations in blood flow around injection areas, plus the amount of fat present, can mean the medication absorbs at slightly different rates